Dr. Jessica Altman, a CML expert from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the changing treatment landscape in CML and what it means for patients. Dr. Altman explains that there are number of therapies available for newly diagnosed patients and for patients that need to switch therapies due to a lack of optimal response or lack of tolerability to initial treatment. Dr. Altman expresses that this continues to be a positive time in CML and how evolving research will benefit a patient's overall quality of life. Editor's Note (12/20/13): In this interview, Dr. Jessica Altman discuses the drug ponatinib, which, at the time of this interview, had been temporarily pulled from the US market at the request of the Food and Drug Administration (FDA) due to safety concerns. Marketing and distribution of this drug has now resumed in the United States, with updated indication, safety and recommendation information.
View more programs featuring Jessica Altman, MD
Produced in association with Northwestern Medicine
Be the first to know about new programs and information with email alerts.